CuraGenex drives Saudi Arabia's leadership in biotechnology and genomics.
Inspired by the National Biotechnology Strategy and fully aligned with Vision 2030, CuraGenex was founded to help shape a future where genomics is embedded at the heart of healthcare, research, and innovation in the Kingdom.
Our mission is to contribute to a healthcare system that is predictive rather than reactive, personalized rather than generalized, and innovation-driven rather than technology-dependent.
Comprehensive Genomic Capabilities
Through its fully integrated genomic infrastructure,
CuraGenex provides an
end-to-end portfolio of advanced services
across testing, analysis,
interpretation, and clinical support.
Clinical Genetic Testing
Clinical genetic testing analyzes an individual's DNA to identify inherited conditions, disease risks, and genetic variations that may affect health. It supports accurate diagnosis, guides treatment decisions, and enables personalized care plans.
Rare Disease Diagnostics
Rare disease diagnostics use advanced genomic technologies to uncover the genetic causes of complex and undiagnosed conditions, shortening the diagnostic journey for patients and families.
Oncology Molecular Profiling
Oncology molecular profiling examines tumor-specific genetic alterations to guide precision cancer treatment, helping clinicians select targeted therapies and monitor disease progression.
Whole-Exome Sequencing (WES)
Whole-exome sequencing focuses on the protein-coding regions of the genome, where most disease-causing variants occur, providing high-resolution insights into genetic mutations.
Whole-Genome Sequencing (WGS)
Whole-genome sequencing analyzes the entire DNA sequence, including coding and non-coding regions, offering the most complete view of an individual's genetic profile.
PCR-Based and RT-PCR–Based Molecular Assays
PCR and RT-PCR assays are highly sensitive techniques used to detect and quantify specific DNA or RNA targets, playing a critical role in infectious disease testing and genetic screening.
Investment in National Genomic Infrastructure
Designed in alignment with the national biotechnology and genomics strategy, the company has committed significant long-term resources to build sovereign infrastructure rather than short-term testing services.
Advanced Laboratory
Infrastructure
Designed in alignment with the national biotechnology and genomics strategy, the company has committed significant long-term resources to build sovereign infrastructure rather than short-term testing services.
Secure In-Country Data
Platforms
Designed in alignment with the national biotechnology and genomics strategy, the company has committed significant long-term resources to build sovereign infrastructure rather than short-term testing services.
Specialized Scientific
Leadership
Designed in alignment with the national biotechnology and genomics strategy, the company has committed significant long-term resources to build sovereign infrastructure rather than short-term testing services.
Advanced Bioinformatics
Pipeline
Designed in alignment with the national biotechnology and genomics strategy, the company has committed significant long-term resources to build sovereign infrastructure rather than short-term testing services.
Contact us
Have questions about our genomic solutions or interested in a partnership? Our team of experts is ready to assist you.